Immune cell mediated cabozantinib resistance for patients with renal cell carcinoma

Renal cell carcinoma (RCC) is the third most common genitourinary cancer in the USA. Despite recent advances in the treatment for advanced and metastatic clear cell RCC (ccRCC), the 5-year relative survival rate for the distant disease remains at 12%. Cabozantinib, a tyrosine kinase inhibitor (TKI),...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Keon Young, Hefti, Hunter O, Liu, Peng, Lugo-Cintrón, Karina M, Kerr, Sheena C, Beebe, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730366/
https://www.ncbi.nlm.nih.gov/pubmed/34931665
http://dx.doi.org/10.1093/intbio/zyab018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8730366/
https://www.ncbi.nlm.nih.gov/pubmed/34931665
http://dx.doi.org/10.1093/intbio/zyab018

Ejemplares similares